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In Search of the Perfect Grasp*Jason H. Rogers, MD, Thomas Smith, MDT he MitraClip (Abbott Vascular, Santa Clara,California) procedure is simple in concept.A small “clip” with moveable arm and
gripper elements is used singly or in multiples to
grasp the leading edges of the anterior and posterior
mitral leaﬂets, bringing them closer together and
improving coaptation. Although the basic design of
the MitraClip and catheter delivery system have not
changed signiﬁcantly since the ﬁrst human implant
in 2003, our understanding of MitraClip positioning
and manipulation has improved considerably. Every
knob on the MitraClip delivery system has a function
that can improve clip alignment, orientation, and
grasping. In addition, intraprocedural imaging of the
mitral valve apparatus has advanced, especially with
the availability of real-time 3-dimensional transeso-
phageal echocardiography (TEE). The ultimate goal
of any MitraClip procedure is to obtain a “perfect
grasp” (Figure 1). In an ideal situation, both the ante-
rior and posterior leaﬂets are clearly imaged on TEE,
then they are securely grasped by the MitraClip and
brought together as the clip is tightened. Despite
the reliable mechanical performance of the MitraClip
device, there are many procedural challenges to actu-
ally grasping the leaﬂets, especially in patients with
severe mitral regurgitation (MR). By deﬁnition, the
gap between leaﬂets is larger in severe MR. The leaf-
lets themselves may ﬂail with excessive motion, or
they may be restricted in movement and highly teth-
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Structural Heart.deep leaﬂet scallops or clefts, or potential mitral
stenosis—all of which make grasping the leaﬂets
more challenging. There can be inherent limitations
to intraprocedural TEE imaging. Some patients have
poor ultrasound “windows,” making visualization a
challenge. Despite an adequate grasp, native leaﬂet
pathology or ventricular function can change over
time, affecting the durability of MitraClip repair.
Finally, it is possible to lose leaﬂet insertion over
time. This phenomenon has been given several
names including “partial clip detachment” and
“single leaﬂet device attachment” (SLDA).
As clinicians, we care about achieving a durable
result with MitraClip therapy. Discussions regarding
the management of patients with recurrent MR
after MitraClip therapy began during the landmark
EVEREST (Endovascular Valve Edge-to-Edge Repair
Study) I and II trials. In these trials, clinical experi-
ence with the device was still early, and procedural
outcomes showed a learning curve. In the EVEREST
phase I clinical trial, 27 patients were enrolled with
only 18 patients (67%) having #2þ MR at discharge,
and 3 patients having partial clip detachment from 1
leaﬂet (1). In the EVEREST II trial, procedural efﬁcacy
improved with per-protocol success rates of 72% for
the primary endpoint of freedom from death, surgery,
or MR 3 to 4þ. Partial clip detachment was also
reduced to 9 of 184 patients (4.9%) randomized to
MitraClip therapy (2). In the EVEREST trials, repeat
MitraClip procedures were not allowed and proce-
dural failures were treated with surgical intervention.
Many patients in EVEREST II who were referred for
surgery after MitraClip procedures had successful
mitral valve repair, but others required mitral valve
replacement. The need for replacement was related
in part to baseline complex anterior mitral valve
pathology and was not necessarily due to the previ-
ous MitraClip attempt or inadequate grasping per
se (3). In recent real-world registries, the rates of
FIGURE 1 The Perfect Grasp
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1491SLDA are low. In the ACCESS-EU (A Two-Phase
Observational Study of the MitraClip System in
Europe) study, a European prospective, multicenter,
post-approval registry of 567 patients at 14 centers
(71% with functional MR), 27 patients had an SLDA
event (4.8%), with all but 1 diagnosed within
6 months of the index procedure. Of these 27
patients, 10 had additional MitraClip procedures,
6 underwent mitral valve surgery, and 11 had no
additional therapy (4). Finally, in the STS/ACC TVT
(Society of Thoracic Surgeons/American College of
Cardiology Transcatheter Valve Therapy) MitraClip
registry of 564 patients treated at 61 U.S. hospitals
(86% with degenerative MR), the 30-day reported
SLDA rate was only 1.1% (5).From left to right, both the anterior and posterior mitral leaﬂets are seen resting on
the MitraClip arms, after which the grippers (arrows) are lowered, capturing the leaﬂets
as the clip is closed. A ¼ anterior; Ao ¼ aorta; LA ¼ left atrium; LV ¼ left ventricle;
P ¼ posterior.
SEE PAGE 1480In this issue of JACC: Cardiovascular In-
terventions, Kreidel et al. (6), from a high volume
MitraClip center in Germany, report on their fasci-
nating experience with 21 patients (of 410 total pa-
tients treated with MitraClip) undergoing a second
MitraClip procedure for recurrent MR at a mean of
6.3 months after the index procedure. Patients in
this series received an average of 1.4 clips, mostly
placed centrally and medially along the mitral valve
coaptation plane. The investigators present their
results in the context of TEE ﬁndings at the time of
the index procedure versus at follow-up. A novel
aspect of their analysis is their introduction of the
term “LLI,” referring to “loss of leaﬂet insertion.”
They have deﬁned LLI as loss of leaﬂet attachment
or insertion into the clip arms in follow-up due
to either of the following situations: 1) increased
leaﬂet mobility at the grasping site (through
possible leaﬂet tear or perforation); or 2) complete
separation of the leaﬂet from the clip (partial clip
detachment). If patients did not have any evidence
of LLI, they were deﬁned as having “adequate
leaﬂet insertion.”
When analyzing their follow-up procedures, the
main conclusions of the investigators are as follow:
1) although repeat MitraClip procedures are feasible,
the success rate of repeat MitraClip procedures
(61.9%) is lower than the index treatment success
(90.8%); 2) patients who returned for repeat pro-
cedures with LLI had success rates of 25% (2 of 8)
versus 85% (11 of 13) for those patients with adequate
leaﬂet insertion; 3) survival is worse for those
patients who require repeat procedures. It was en-
couraging that only 8 of 410 patients treated (1.95%)
had evidence of LLI on follow-up, reinforcing that
this is an infrequent event, much like SLDA as
described in other registries.An intriguing aspect of the report by Kreidel et al.
(6) is that loss of leaﬂet insertion was only partially
responsible for recurrent MR. The majority of patients
in this series had functional MR (71.4%) with systolic
heart failure and depressed left ventricular (LV)
ejection fractions. Importantly, in the patients with
adequate leaﬂet insertion who developed recurrent
MR, LV volume increased substantially over time,
supporting the idea that recurrent MR can be related
to progressive LV dilation despite successful leaﬂet
grasping. This underscores the adage that functional
mitral regurgitation is a ventricular disease. It is also
interesting that most repeat clips were placed lateral
to the original clips. This would also suggest pro-
gressive LV dysfunction with annular septal lateral
dilation as opposed to primary clip failure. Why some
patients developed progressive LV enlargement over
time despite a successful index procedure, whereas
others did not, is not known.
In summary, this report is of importance because
there is a paucity of data available on the outcomes of
patients who undergo repeat MitraClip procedures.
In the ﬁnal analysis, it would appear that recurrent
MR after MitraClip procedures could be due to
multiple mechanisms in spite of adequate leaﬂet
grasping at the initial procedure. Patients who deve-
lop recurrent MR due to LLI likely have inherent
complex leaﬂet pathology to begin with, and this may
predispose them to progressive leaﬂet degeneration
over time. Of course, obtaining the best possible grasp
at the index procedure is of paramount importance
and the investigators provide some clear examples
of how to measure leaﬂet insertion quantitatively.
At our center, we have a “grasp vote” as a team, and
Rogers and Smith J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 1 , 2 0 1 5
In Search of the Perfect Grasp S E P T E M B E R 2 0 1 5 : 1 4 9 0 – 2
1492only release the clip when all participants in the
procedure (echocardiographer and interventionalist)
agree that the grasp is adequate. The decision to
release the MitraClip depends on a collective review
of quantitative techniques to measure leaﬂet inser-
tion in the LV outﬂow tract, bicommissural, 4 cham-
ber, 3-dimensional, and occasionally transgastric
echocardiographic views. We also record the entire
grasping sequence (up to a 15-second acquisition loop)
for subsequent review, frame by frame if needed, to
assess leaﬂet insertion. Finally, we must all remember
that MR can arise from numerous aberrations of themitral valve apparatus, and that durable reduction
of MR will depend not only on adequate leaﬂet
grasping, but also on careful attention to guideline-
directed medical therapy for heart failure, resynchro-
nization therapy when appropriate, maintenance of
sinus rhythm, and preservation of LV function.
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